Are you Dr. Chadburn?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 81 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
525 E 68th St 715
New York, NY 10065Phone+1 212-746-6631Fax+1 212-746-8173
Summary
- Dr. Amy Chadburn, MD is a board certified pathologist in New York, New York. She is currently licensed to practice medicine in New York, Illinois, and Oregon. She is affiliated with New York-Presbyterian Hospital and is a Professor in Pathology at Northwestern University Medical School.
Education & Training
- New York Presbyterian Hospital (Columbia Campus)Fellowship, Hematopathology, 1989 - 1990
- New York Presbyterian Hospital (Cornell Campus)Residency, Pathology-Anatomic and Clinical, 1984 - 1988
- University of Rochester Medical CenterInternship, Transitional Year, 1983 - 1984
- Stanford University School of MedicineClass of 1983
Certifications & Licensure
- IL State Medical License 2008 - 2026
- NY State Medical License 1984 - 2025
- OR State Medical License 1992 - 2025
- American Board of Pathology Anatomic Pathology & Clinical Pathology
- American Board of Pathology Hematology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Top Doctors: New York Metro Area Castle Connolly, 2003-2009
- New York Magazine: Top Doctors Castle Connolly, 2007-2008
Clinical Trials
- Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Start of enrollment: 2013 Mar 05
Publications & Presentations
PubMed
- Lethal COVID-19 associates with RAAS-induced inflammation for multiple organ damage including mediastinal lymph nodes.Michael J Topper, Joseph W Guarnieri, Jeffrey A Haltom, Amy Chadburn, Henry Cope
Proceedings of the National Academy of Sciences of the United States of America. 2024-12-03 - EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.Yusuke Isshiki, Xi Chen, Matt Teater, Ioannis Karagiannidis, Henna Nam
Cancer Cell. 2024-11-30 - 8 citationsSMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.Qing Deng, Priya Lakra, Panhong Gou, Haopeng Yang, Cem Meydan
Cancer Cell. 2024-04-08